KPTIHealthcareMicro-Cap
Karyopharm Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Karyopharm Therapeutics Inc. (KPTI), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are KPTI insiders buying or selling?
Karyopharm Therapeutics Inc. insiders reported 4 open-market buys ($390.3K) and 230 sells ($55.8M) across 234 Form 4 filings — a net selling position of $55.4M.
Source: SEC EDGAR Form 4
Key Statistics (as of May 15, 2026)
Total Form 4 filings
234
SEC EDGAR
Insider filers
20
Insider buys (4)
$390.3K
Insider sells (230)
$55.8M
Insider sentiment
Net sellingNet insider flow of $55.4M in net selling.
Recent KPTI insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 15, 2026 | Stuart Poulton | EVP, Chief Development Officer | Sale | 403 | $9.50 | $3.8K |
| May 15, 2026 | Reshma Rangwala | EVP & Chief Medical Officer | Sale | 408 | $9.50 | $3.9K |
| May 15, 2026 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | Sale | 324 | $9.50 | $3.1K |
| May 15, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 53 | $9.50 | $503.5 |
| May 15, 2026 | Richard A. Paulson | President and CEO | Sale | 2.2K | $9.50 | $20.9K |
| May 15, 2026 | Michael Mano | EVP, CLO&Secretary | Sale | 266 | $9.50 | $2.5K |
| Apr 22, 2026 | Reshma Rangwala | EVP & Chief Medical Officer | Sale | 449 | $8.94 | $4.0K |
| Mar 3, 2026 | Richard A. Paulson | President and CEO | Sale | 12.4K | $9.41 | $116.3K |
| Mar 3, 2026 | Stuart Poulton | EVP, Chief Development Officer | Sale | 5.1K | $9.41 | $48.0K |
| Feb 19, 2026 | Stuart Poulton | EVP, Chief Development Officer | Sale | 378 | $8.63 | $3.3K |
| Feb 4, 2026 | Lori Macomber | EVP, CFO & Treasurer | Sale | 1.6K | $6.30 | $10.2K |
| Jan 29, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 50 | $7.03 | $351.5 |
| Jan 22, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 265 | $5.96 | $1.6K |
| Oct 3, 2025 | Kristin Abate | Chief Accounting Officer | Sale | 362 | $6.30 | $2.3K |
| Sep 16, 2025 | Richard A. Paulson | President and CEO | Sale | 1.3K | $6.43 | $8.1K |
| Sep 16, 2025 | Michael Mano | SVP, General Counsel&Secretary | Sale | 234 | $6.43 | $1.5K |
| Sep 16, 2025 | Stuart Poulton | EVP, Chief Development Officer | Sale | 401 | $6.43 | $2.6K |
| Sep 16, 2025 | Reshma Rangwala | EVP & Chief Medical Officer | Sale | 408 | $6.43 | $2.6K |
| Sep 16, 2025 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | Sale | 325 | $6.43 | $2.1K |
| Sep 16, 2025 | Kristin Abate | Chief Accounting Officer | Sale | 23 | $6.43 | $147.89 |
| Sep 4, 2025 | Kristin Abate | Chief Accounting Officer | Sale | 12 | $6.78 | $81.36 |
| Jul 30, 2025 | Stuart Poulton | EVP, Chief Development Officer | Sale | 191 | $4.37 | $834.67 |
| Jul 23, 2025 | Kristin Abate | Chief Accounting Officer | Sale | 238 | $4.00 | $952 |
| May 7, 2025 | Richard A. Paulson | President and CEO | Sale | 236 | $7.12 | $1.7K |
| Apr 24, 2025 | Reshma Rangwala | EVP & Chief Medical Officer | Sale | 419 | $6.17 | $2.6K |
Showing the 25 most recent of 234 Form 4 filings for Karyopharm Therapeutics Inc..
Most active KPTI insiders
- Michael Kauffman41 filings
- Richard A. Paulson41 filings
- Sharon Shacham41 filings
- Michael Mason12 filings
- Stuart Poulton12 filings
Ask anything about KPTI insider activity
Use Trabud's AI agent to query Karyopharm Therapeutics Inc.'s Form 4 history in plain English — "Show me KPTI CEO purchases this year" or compare it against any other ticker.
Open the AI agentKPTI insider trading FAQ
Are Karyopharm Therapeutics Inc. insiders buying or selling?
Across 234 SEC Form 4 filings, Karyopharm Therapeutics Inc. (KPTI) insiders reported 4 open-market purchases totaling $390.3K and 230 sales totaling $55.8M. That is a net selling position of $55.4M.
How many insiders trade KPTI stock?
20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Karyopharm Therapeutics Inc.. The most recent filing was accepted on May 15, 2026.
Where does Trabud get KPTI insider trading data?
All KPTI insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.